HC Wainwright Issues Optimistic Estimate for ACRV Earnings

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Equities researchers at HC Wainwright boosted their Q3 2026 earnings estimates for shares of Acrivon Therapeutics in a research report issued on Thursday, August 13th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($0.48) per share for the quarter, up from their prior estimate of ($0.53). The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($1.77) per share. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q4 2026 earnings at ($0.53) EPS, FY2026 earnings at ($1.92) EPS, FY2027 earnings at ($1.31) EPS, FY2028 earnings at ($0.85) EPS and FY2029 earnings at ($0.60) EPS.

Acrivon Therapeutics (NASDAQ:ACRV) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.07.

Separately, Weiss Ratings cut Acrivon Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $13.50.

Acrivon Therapeutics Stock Performance

Shares of NASDAQ:ACRV opened at $2.05 on Monday. The company has a market cap of $87.74 million, a P/E ratio of -1.09 and a beta of 1.85. Acrivon Therapeutics has a one year low of $1.27 and a one year high of $3.56. The business’s 50-day simple moving average is $1.71 and its 200 day simple moving average is $1.68.

Hedge Funds Weigh In On Acrivon Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Focus Partners Wealth acquired a new stake in shares of Acrivon Therapeutics during the third quarter valued at about $36,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Acrivon Therapeutics in the fourth quarter worth about $40,000. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Acrivon Therapeutics in the fourth quarter worth about $44,000. Quadrature Capital Ltd purchased a new position in Acrivon Therapeutics in the fourth quarter valued at about $50,000. Finally, Invesco Ltd. purchased a new position in Acrivon Therapeutics in the first quarter valued at about $72,000. 71.62% of the stock is owned by hedge funds and other institutional investors.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.